The Innovative Research and Development Team of Gynecological Malignant Tumor Prevention Strategy

Team Leader: Professor Lyu Wei-guo

Overview:

The innovation team consists of 20 people, including 6 people with senior professional titles and 10 vice-high professional titles; 16 with doctorates and 6 people under 40. The innovation team has 2 recipients of the State Council's special allowance, 2 national youths, 1 national and family planning committee, and 1 young and middle-aged expert with outstanding contributions from Zhejiang Province. 1 with 1 chairman of the Chinese Medical Association's Gynecologic Oncology Branch, 1 member of the Chinese Medical Association's Obstetrics and Gynecology Branch Standing Committee, 2 members of the Chinese Medical Association's Gynecologic Oncology Branch, and 1 young deputy director of the Chinese Medical Association's Gynecological Oncology Branch. . In the past 5 years, the team members have undertaken 2 national key R & D projects (1 project leader and 1 project leader), 1 demonstration application research of the clinical medical research collaborative network construction of the Ministry of Science and Technology, 24 National Natural Science Funds, and the Provincial Science and Technology Department 1 major project; published more than 200 papers included in SCI, including more than 10 papers with IF ≥ 5 points and 5 papers with IF ≥ 10 points. Won 4 national invention patents. In recent years, he has won two second prizes for national scientific and technological progress, one first prize for Chinese medical science and technology, and two first prizes for scientific and technological progress of the Ministry of Education.

The professional areas of the innovation team include gynecological oncology, assisted reproduction, gynecological pathology, medicine, imaging, testing, tumor bioinformatics analysis, molecular biology technology, and computers. Cooperated with assisted reproduction, pathology, imaging, laboratory and other disciplines to preserve fertility in young gynecological malignancies, enabling 300 young patients to have normal babies, and thousands of patients to retain female functions. Published SCI in cooperation with relevant departments More than 10 papers. A number of phase III multi-center clinical trials in the diagnosis and treatment of gynecological malignancies and clinical medicines have been jointly conducted with several university affiliated hospitals across the country. He has cooperated with clinical pharmacy to carry out exploratory research on tumor drug resistance suppression strategies. He has published 3 SCI papers, and won one National Science and Technology Progress Award in 2011 and one Ministry of Education Science and Technology Progress Award in 2017. In recent years, it has cooperated with Hangzhou Detong Biotechnology Co., Ltd. in the research and development and clinical application of HPV detection reagents, and has obtained 2 national Class III medical device product registration certificates and 5 national invention patents. In cooperation with the School of Computer and Software of Zhejiang University, an exploratory study on the application of artificial intelligence (AI) in the diagnosis and treatment of gynecological malignancies, including AI for colposcopy, etc. The relevant research results have been exchanged at the 2018 IGCS Annual Meeting.